IRON TRIANGLE PARTNERS LP
Q1 2024 Form 13-F
COS COB, CONNECTICUT
CIK 0001779763
· CRD 302077
· SEC-registered investment adviser
$976.3M Reported Value Total
IRON TRIANGLE PARTNERS LP reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,128,405,652, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
2 funds
· $359.6M gross asset value
Hedge Fund: $359.6M
Source: Form ADV filed 2026-03-24
Reported value
$976.3M
Quarter over quarter
+13.0%
Holdings
28
Top-10 concentration
53.2%
Key People
Form ADV owners & control persons
Kevin Thomas Molloy
LIMITED PARTNER
Michael John O'Brien
CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 15, 2024 |
| Form | 13F-HR |
| Reported value | $976.3M |
| Positions | 28 |
| Change in reported value | +26.3% |
| New positions | 13 |
| Exited positions | 11 |
| Position turnover | 61.5% |
| Top-10 concentration | 53.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2025 13F
Filed Feb 17, 2026
|
27 | $874.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
25 | $703.3M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
26 | $651.2M |
|
Q1 2025 13F
Filed May 15, 2025
|
27 | $634.4M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
22 | $908.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
24 | $721.8M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
24 | $983.7M |
|
Q1 2024 13F
Filed May 15, 2024
|
28 | $976.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
26 | $772.9M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
23 | $684.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
22 | $748.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
27 | $693.2M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
26 | $557.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
27 | $572.0M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
24 | $771.2M |
|
Q1 2022 13F
Filed May 16, 2022
|
28 | $840.7M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
25 | $717.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
26 | $696.8M |
|
Q2 2021 13F
Filed Aug 16, 2021
|
26 | $970.8M |
|
Q1 2021 13F
Filed May 17, 2021
|
27 | $786.5M |
5 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ACHC ACADIA HEALTHCARE COMPANY IN | $71.5M | 7.33% |
| 2 | DXCM DEXCOM INC | $65.4M | 6.7% |
| 3 | ICLR ICON PLC | $50.7M | 5.19% |
| 4 | ABBV ABBVIE INC | $50.3M | 5.15% |
| 5 | ISRG INTUITIVE SURGICAL INC | $49.6M | 5.08% |
| 6 | EXAS EXACT SCIENCES CORP | $48.3M | 4.95% |
| 7 | WST WEST PHARMACEUTICAL SVSC INC | $47.4M | 4.85% |
| 8 | ALGN ALIGN TECHNOLOGY INC | $46.6M | 4.77% |
| 9 | ILMN ILLUMINA INC | $45.4M | 4.65% |
| 10 | BRKR BRUKER CORP | $43.8M | 4.49% |
| 11 | GKOS GLAUKOS CORP | $40.5M | 4.15% |
| 12 | TEVA TEVA PHARMACEUTICAL INDS LTD | $39.1M | 4.0% |
| 13 | BKD BROOKDALE SR LIVING INC | $39.0M | 3.99% |
| 14 | APLS APELLIS PHARMACEUTICALS INC | $32.3M | 3.31% |
| 15 | FTRE FORTREA HLDGS INC | $31.8M | 3.25% |
| 16 | NBIX NEUROCRINE BIOSCIENCES INC | $30.3M | 3.11% |
| 17 | AVTR AVANTOR INC | $29.4M | 3.01% |
| 18 | SWAV SHOCKWAVE MED INC | $26.0M | 2.66% |
| 19 | SDGR SCHRODINGER INC | $23.3M | 2.39% |
| 20 | SNDX SYNDAX PHARMACEUTICALS INC | $23.2M | 2.37% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.